Mapi Pharma Advances Once-Monthly Cariprazine Depot After Positive Phase I/IIa Results
NESS ZIONA, Israel, August 12, 2026 Mapi Pharma Ltd. announced initial clinical results from its ongoing Phase I/IIa study...
Psychiatry
Advertisement
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Supernus Pharmaceuticals and Indivior to Merge in $2.2 Billion CNS Biopharma Deal
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
Advertisements
Lilly Acquires AtaiBeckley to Advance Depression Therapies
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
TG Therapeutics Launches Phase 2 BRIUMVI Trial
NEW YORK, July 6, 2026 TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI®...
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
Oryzon Raises €12M to Accelerate Clinical Development
MADRID, Spain & CAMBRIDGE, Mass., July 1, 2026 Oryzon Genomics S.A. announced the successful completion of a €12 million...
Otsuka Reports Positive Phase 3b Results for Centanafadine
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
Advertisement
